Table 4 |
||||||||
|
Association study with Ngb haplotypes in LVD and SVD patients |
||||||||
|
Haplotype Poly1/Poly2 |
LVD vs Control |
SVD vs Control |
||||||
|
|
||||||||
|
LVD n (%) |
Control n (%) |
OR (95%CI) |
P |
SVD n (%) |
Control n (%) |
OR (95%CI) |
P |
|
|
|
||||||||
|
c-6a |
131.91(29.8) |
62.48(19.8) |
1.726(1.224–2.434) |
0.002 |
64.59(24.1) |
62.48(19.8) |
1.288(0.869–1.910) |
0.201 |
|
c-5a |
149.09(33.7) |
68.52(21.7) |
1.838(1.318–2.563) |
<0.0001 |
95.42(35.6) |
68.52(21.7) |
1.997(1.384–2.880) |
<0.0001 |
|
t-6a |
92.09(20.8) |
103.53(32.8) |
0.540(0.389–0.750) |
<0.0001 |
62.42(23.3) |
103.53(32.8) |
0.623(0.431–0.900) |
0.011 |
|
t-5a |
68.91(15.6) |
81.47(25.8) |
0.532(0.371–-0.762) |
0.001 |
45.58(17.0) |
81.47(25.8) |
0.590(0.393–0.886) |
0.010 |
|
Global χ2 |
36.407 |
20.966 |
||||||
|
Fisher P |
<0.0001 |
<0.0001 |
||||||
|
|
||||||||
|
Poly1: 89+104 c>t; Poly2: 322-110 (6a)>5a |
||||||||
|
Lin et al. BMC Medical Genetics 2008 9:110 doi:10.1186/1471-2350-9-110 |
||||||||
